The company's ENTRY ™ platform provides therapies designed to treat diseases with unmet medical needs by modulating microRNA. ARTHEx Biotech has world-renowned scientific and clinical advisors to support the successful development of their products. Their first investigational product, ATX-01, is an antimiR in preclinical development for Myotonic Dystrophy Type 1, a rare disease affecting more than 900,000 people worldwide with no cure or approved treatment to date. ATX-01 targets micro-RNA-23b, a key factor in the disease pathogenesis, with a dual and unique mechanism of action, making it a first-in-class disease-modifying therapy.